Skip to main content
SpringerLink
Log in
Book cover

Drug-Induced Lung Injury pp 139–164Cite as

DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs?

  • Chapter
  • First Online:

  • 678 Accesses

Abstract

The standard therapeutic strategy for patients with advanced cancer is treatment with antineoplastic drugs. With the progress in the development of antineoplastic drugs, the prognosis of these patients has improved, despite the difficulty of achieving a complete cure. Molecular target antineoplastic drugs have often provided a paradigm shift in cancer therapy and currently hold a prominent position in cancer therapeutic strategies. While these drugs have clinical benefits, the toxicity profile of these drugs is different from that of conventional cytotoxic chemotherapy. Molecular target antineoplastic drugs consisting of various types of molecules may demonstrate diverse characteristics, although drug-induced lung injury (DLI) is commonly observed in treatment with most of these antineoplastic drugs. In this chapter, reports of DLI associated with molecular target neoplastic drugs were reviewed in order to understand its characteristics and thereby lead to prevention of its occurrence and exacerbation. Diverse patterns of DLI have been commonly observed in patients treated with molecular target antineoplastic drugs, whereas similar DLI patterns have been obtained from various drug types. The incidence and frequency of fatality from DLI also display a wide range. These events were more frequently observed in Japanese patients than in other ethnic groups, suggesting the association of ethnicity with the development and severity of DLI. Clinicians should note the diversity of DLI and the role of ethnicity in DLI in treatment with molecular target antineoplastic drugs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177(12):1348–57. doi:10.1164/rccm.200710-1501OC.

    Article  PubMed  Google Scholar 

  2. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011;258(1):41–56. doi:10.1148/radiol.10092129.

    Article  PubMed  Google Scholar 

  3. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8(4):303–6.

    Article  CAS  PubMed  Google Scholar 

  4. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24(16):2549–56. doi:10.1200/JCO.2005.04.9866.

    Article  CAS  PubMed  Google Scholar 

  5. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10(7):461–6. doi:10.1634/theoncologist.10-7-461.

    Article  CAS  PubMed  Google Scholar 

  6. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892–9. doi:10.1200/JCO.2005.02.840.

    Article  CAS  PubMed  Google Scholar 

  7. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6. doi:10.1200/JCO.2006.07.9525.

    Article  CAS  PubMed  Google Scholar 

  8. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer. 2014;83(2):231–9. doi:10.1016/j.lungcan.2013.11.016.

    Article  PubMed  Google Scholar 

  9. Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J. 2007;14(3):167–70.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2015;88(1):74–9. doi:10.1016/j.lungcan.2015.01.026.

    Article  PubMed  Google Scholar 

  11. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99. doi:10.1056/NEJMoa1411817.

    Article  PubMed  Google Scholar 

  12. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43. doi:10.1056/NEJMoa064320.

    Article  CAS  PubMed  Google Scholar 

  13. Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol. 2010;21(3):474–80. doi:10.1093/annonc/mdp373.

    Article  CAS  PubMed  Google Scholar 

  14. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645–52. doi:10.1056/NEJMoa011573.

    Article  CAS  PubMed  Google Scholar 

  15. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17(3):372–9. doi:10.1093/annonc/mdj057.

    Article  CAS  PubMed  Google Scholar 

  16. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol. 2011;6(4):235–43. doi:10.1007/s11523-011-0199-0.

    Article  PubMed  Google Scholar 

  17. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20(6):1162–4. doi:10.1038/sj.leu.2404207.

    Article  CAS  PubMed  Google Scholar 

  18. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143–50. doi:10.1182/blood-2006-11-056028.

    Article  CAS  PubMed  Google Scholar 

  19. Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176(8):814–8. doi:10.1164/rccm.200705-715CR.

    Article  CAS  PubMed  Google Scholar 

  20. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brummendorf TH, Porkka K, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123(9):1309–18. doi:10.1182/blood-2013-07-513937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol. 2010;47(4):344–53. doi:10.1053/j.seminhematol.2010.06.002.

    Article  CAS  PubMed  Google Scholar 

  22. Go SI, Lee WS, Lee GW, Kang JH, Kang MH, Lee JH, et al. Nilotinib-induced interstitial lung disease. Int J Hematol. 2013;98(3):361–5. doi:10.1007/s12185-013-1398-5.

    Article  PubMed  Google Scholar 

  23. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92. doi:10.1158/2326-6066.CIR-15-0102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. doi:10.1056/NEJMoa1412082.

    Article  CAS  PubMed  Google Scholar 

  26. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. doi:10.1056/NEJMoa1507643.

    Article  CAS  PubMed  Google Scholar 

  27. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. doi:10.1056/NEJMoa1510665.

    Article  CAS  PubMed  Google Scholar 

  28. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–16. doi:10.1001/jamaoncol.2016.2453.

    Article  PubMed  Google Scholar 

  29. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301–11. doi:10.1016/j.ccr.2005.03.003.

    Article  CAS  PubMed  Google Scholar 

  30. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. doi:10.1056/NEJMoa0805019.

    Article  PubMed  Google Scholar 

  31. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84. doi:10.1056/NEJMoa052122.

    Article  CAS  PubMed  Google Scholar 

  32. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71. doi:10.1016/S1470-2045(13)70130-X.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010;182(3):396–403. doi:10.1164/rccm.200911-1720OC.

    Article  PubMed  Google Scholar 

  34. Nozawa M, Nonomura N, Ueda T, Nishimura K, Kanayama HO, Miki T, et al. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. Jpn J Clin Oncol. 2013;43(11):1132–8. doi:10.1093/jjco/hyt121.

    Article  PubMed  Google Scholar 

  35. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23. doi:10.1056/NEJMoa1009290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. doi:10.1056/NEJMoa1109653.

    Article  CAS  PubMed  Google Scholar 

  37. Baas MC, Struijk GH, Moes DJ, van den Berk IA, Jonkers RE, de Fijter JW, et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int. 2014;27(5):428–36. doi:10.1111/tri.12275.

    Article  CAS  PubMed  Google Scholar 

  38. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81. doi:10.1056/NEJMoa066838.

    Article  CAS  PubMed  Google Scholar 

  39. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107(9):3492–4. doi:10.1182/blood-2005-11-4541.

    Article  CAS  PubMed  Google Scholar 

  40. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–52. doi:10.1056/NEJMoa1411321.

    Article  PubMed  Google Scholar 

  41. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34. doi:10.1056/NEJMoa1516282.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji-shi, Tokyo, 193-0998, Japan

    Nobuyuki Koyama

Authors
  1. Nobuyuki Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuyuki Koyama .

Editor information

Editors and Affiliations

  1. First Department of Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan

    Masayuki Hanaoka

  2. Ibaraki Medical Center, Tokyo Medical University, Ibaraki, Japan

    Hiroyuki Nakamura

  3. Ibaraki Medical Center, Tokyo Medical University, Ibaraki, Japan

    Kazutetsu Aoshiba

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Koyama, N. (2018). DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs?. In: Hanaoka, M., Nakamura, H., Aoshiba, K. (eds) Drug-Induced Lung Injury. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-10-4466-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-4466-3_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-4465-6

  • Online ISBN: 978-981-10-4466-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation